NYSEAMERICAN:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ATNM Stock Alerts $7.13 +0.28 (+4.09%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$6.82▼$7.3450-Day Range N/A52-Week Range$4.00▼$9.86Volume192,608 shsAverage Volume328,635 shsMarket Capitalization$209.62 millionP/E RatioN/ADividend YieldN/APrice Target$25.72 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Actinium Pharmaceuticals alerts: Email Address Actinium Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside260.7% Upside$25.72 Price TargetShort InterestBearish7.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to $0.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.13 out of 5 stars 3.5 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.45% of the outstanding shares of Actinium Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverActinium Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Actinium Pharmaceuticals has recently increased by 20.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATNM. Previous Next 2.6 News and Social Media Coverage News SentimentActinium Pharmaceuticals has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Actinium Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 38 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 27.50% of the stock of Actinium Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.87) to $0.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 5.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.Read More ATNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATNM Stock News HeadlinesApril 22, 2024 | tmcnet.comLEAP Boosts Global Customer Reach with Vonage SIP Trunking API IntegrationApril 20, 2024 | msn.comGoogle is shutting down the PaLM API for most usersApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 18, 2024 | markets.businessinsider.comActinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML PatientsApril 18, 2024 | prnewswire.comActinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 12, 2024 | msn.comMeta Welcomes Developers to Threads with Open API DocumentationApril 10, 2024 | venturebeat.comOpenAI makes GPT-4 Turbo with Vision generally available through its APIApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 9, 2024 | tmcnet.comMyCompanyWorks launches EntityMachine™, the Innovative Business Entity Formation and Management APIApril 9, 2024 | 9to5mac.comMeta shares more details on Threads API ahead of June releaseApril 9, 2024 | finance.yahoo.comThe API Innovation Center, Apertus Pharmaceuticals Bring API Production of Critical Generic Cancer Drug to U.S. SoilApril 9, 2024 | finance.yahoo.comGlobal Pharmaceutical CDMO Market Analysis Report 2024-2030: AI-Assisted Drug Active Pharmaceutical Ingredient (API) Synthesis Gaining AttentionApril 9, 2024 | tmcnet.comMEF Pioneers Industry Leading Enterprise Business and Operational LSO API Portfolio for Network ServicesApril 4, 2024 | stockhouse.comNextdoor Launches Ads API Program, Offering Advertisers an Easier Way to Extend Their Campaigns to NextdoorApril 3, 2024 | markets.businessinsider.comActinium Pharmaceuticals: Strong Buy Rating on Financial Health and Promising PipelineApril 2, 2024 | tmcnet.comHasura Supergraph Brings Unparalleled On-Demand Composability to APIs to Address Data and API Integration ChallengesApril 2, 2024 | finance.yahoo.comGlobal High Potency API Contract Manufacturing Market Expects Growth with a CAGR of 8.42% Through 2028April 2, 2024 | finance.yahoo.comBitwarden Enhances Passwordless.dev Tools with Magic Links API to Streamline Passwordless AuthenticationApril 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)April 1, 2024 | markets.businessinsider.comActinium's Phase 3 Trial Results Show Survival Benefit In Acute Myeloid Leukemia Patients; Stock UpApril 1, 2024 | finance.yahoo.comActinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual MeetingMarch 26, 2024 | finance.yahoo.comActinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyMarch 26, 2024 | prnewswire.comActinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyMarch 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Actinium Pharmaceuticals (ATNM)March 19, 2024 | msn.comActinium spikes as H.C. Wainwright highlights buyout prospects after Fusion dealMarch 16, 2024 | venturebeat.comForge’s API raises bar for player rewards and engagementSee More Headlines Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2023Today4/23/2024Next Earnings (Estimated)5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webwww.actiniumpharmaceuticals.com Phone(646) 677-3870FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$25.72 High Stock Price Target$50.00 Low Stock Price Target$11.60 Potential Upside/Downside+260.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,820,000.00 Net MarginsN/A Pretax Margin-60,269.13% Return on Equity-102.64% Return on Assets-52.57% Debt Debt-to-Equity RatioN/A Current Ratio9.21 Quick Ratio9.21 Sales & Book Value Annual Sales$80,000.00 Price / Sales2,620.28 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book5.44Miscellaneous Outstanding Shares29,400,000Free Float28,220,000Market Cap$209.62 million OptionableNot Optionable Beta0.01 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Sandesh C. Seth M.B.A. (Age 60)M.S., Chairman & CEO Comp: $1.15MMr. Steven O'Loughlin BS (Age 38)CFO & Corporate Secretary Comp: $585kDr. Paul Diamond Esq.Ph.D., Vice President of Patent & Legal CounselDr. David GouldSenior Vice President of Corporate Development & Corporate AffairsDr. Bernie Cunningham P.M.P.Ph.D., Executive Director of Clinical Supply Chain & Logistics and CMC Project ManagementDr. Qing LiangVP & Head of Radiation SciencesDr. Avinash Desai M.D.Chief Medical OfficerMs. Jenny HsiehChief Strategy OfficerMs. Sunitha LakshminarayananSenior VP, Head of CMC & Product DevelopmentMs. Elaina HaeuberVP & Head of Clinical OperationsMore ExecutivesKey CompetitorsAldeyra TherapeuticsNASDAQ:ALDXConduit PharmaceuticalsNASDAQ:CDTuniQureNASDAQ:QUREOvid TherapeuticsNASDAQ:OVIDVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInstitutional OwnershipSanders Morris Harris LLCBought 10,000 shares on 4/11/2024Ownership: 0.034%Intrepid Financial Planning Group LLCSold 2,000 shares on 2/13/2024Ownership: 0.058%Simplex Trading LLCBought 1,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions ATNM Stock Analysis - Frequently Asked Questions Should I buy or sell Actinium Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATNM shares. View ATNM analyst ratings or view top-rated stocks. What is Actinium Pharmaceuticals' stock price target for 2024? 5 brokerages have issued 12-month price targets for Actinium Pharmaceuticals' stock. Their ATNM share price targets range from $11.60 to $50.00. On average, they expect the company's stock price to reach $25.72 in the next twelve months. This suggests a possible upside of 260.7% from the stock's current price. View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts. How have ATNM shares performed in 2024? Actinium Pharmaceuticals' stock was trading at $5.24 at the beginning of the year. Since then, ATNM stock has increased by 36.1% and is now trading at $7.13. View the best growth stocks for 2024 here. Are investors shorting Actinium Pharmaceuticals? Actinium Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,190,000 shares, an increase of 20.3% from the March 15th total of 1,820,000 shares. Based on an average daily volume of 332,600 shares, the days-to-cover ratio is currently 6.6 days. View Actinium Pharmaceuticals' Short Interest. When is Actinium Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our ATNM earnings forecast. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) announced its earnings results on Monday, April, 3rd. The biotechnology company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.01. When did Actinium Pharmaceuticals' stock split? Shares of Actinium Pharmaceuticals reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO). Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (0.03%). View institutional ownership trends. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:ATNM) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
